Transthyretin Amyloidosis With Cardiomyopathy clinical trials

Explore recruiting transthyretin amyloidosis with cardiomyopathy clinical trials.

Recruiting transthyretin amyloidosis with cardiomyopathy studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Transthyretin Amyloidosis With Cardiomyopathy trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Denmark, Belgium, Italy, Sweden, Czechia, Netherlands +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Ireland, Portugal, Denmark, Czechia, Lithuania, Germany +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double‑Blind, Placebo‑Controlled Study to Evaluate the Efficacy and Safety of NTLA‑2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR‑CM).

Italy, Germany, France, Spain, Sweden, Denmark +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)

France, Germany, Italy, Greece, Belgium, Portugal +12 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

Spain, Denmark, Netherlands, Belgium, Norway, Portugal +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

(23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis.

Austria, Germany, Italy, Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Transthyretin Amyloidosis With Cardiomyopathy trials by city

Transthyretin Amyloidosis With Cardiomyopathy clinical trials

Recruiting transthyretin amyloidosis with cardiomyopathy studies right now

A Phase I/IIa，Open-label, Single Ascending Dose and Dose-expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of YOLT-201 in Patients With Transthyretin Amyloidosis Polyneuropathy (ATTR-PN) or Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

PATHWAY-RCT: Preventing Admission To Hospital With Attr cardiomyopathY

A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis

An Interventional Pilot Study to Investigate the Feasibility and Acceptance of a Structured Psychological Support Program for Patients, Caregivers, and Presymptomatic Carriers in Hereditary Transthyretin Amyloidosis With Cardiomyopathy

A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.

TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Enavogliflozin for the Management of Patients With Amyloid CardiomyopaThy

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

Also recruiting in Europe

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

MAGNITUDE: A Phase 3, Multinational, Multicenter, Randomized, Double‑Blind, Placebo‑Controlled Study to Evaluate the Efficacy and Safety of NTLA‑2001 in Participants with Transthyretin Amyloidosis with Cardiomyopathy (ATTR‑CM).

TRITON-CM: A Phase 3 Global, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Transthyretin-Mediated Amyloidosis with Cardiomyopathy (ATTR amyloidosis with cardiomyopathy)

An Open-Label Extension Study to Assess the Safety and Efficacy of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)

(23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis.

Transthyretin Amyloidosis With Cardiomyopathy trials by city

Other conditions